Raia Drogasil (Raia Drogasil) Operating Income : $415 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Raia Drogasil Operating Income?

Raia Drogasil's Operating Income for the three months ended in Mar. 2024 was $105 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $415 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Raia Drogasil's Operating Income for the three months ended in Mar. 2024 was $105 Mil. Raia Drogasil's Revenue for the three months ended in Mar. 2024 was $1,827 Mil. Therefore, Raia Drogasil's Operating Margin % for the quarter that ended in Mar. 2024 was 5.77%.

Good Sign:

Raia Drogasil SA operating margin is expanding. Margin expansion is usually a good sign.

Raia Drogasil's 5-Year average Growth Rate for Operating Margin % was 3.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Raia Drogasil's annualized ROC % for the quarter that ended in Mar. 2024 was 10.13%. Raia Drogasil's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 18.81%.

Raia Drogasil Operating Income Historical Data

The historical data trend for Raia Drogasil's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raia Drogasil Operating Income Chart

Raia Drogasil Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

218.26

182.52

243.06

349.67

396.77

Raia Drogasil Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Income	Get a 7-Day Free Trial															82.83	127.70	97.83	84.30	105.44

Raia Drogasil Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $415 Mil.

Raia Drogasil (OTCPK:RADLY) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Raia Drogasil's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	421.74 * ( 1 - 30.98% )	/	( (2896.035	+	2848.519)	/ 2 )
=	291.084948	/	2872.277
=	10.13 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4101.068	-	1120.882	-	( 84.151	-	max(0, 1648.944	-	2359.622	+	84.151	))
=	2896.035

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4147.085	-	1215.712	-	( 82.854	-	max(0, 1684.081	-	2415.409	+	82.854	))
=	2848.519

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Raia Drogasil's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	397.696	/	( ( (1211.822 + max(915.847, 0))	+	(1221.181 + max(879.005, 0)) )	/	2 )
=	397.696	/	( ( 2127.669	+	2100.186 )	/	2 )
=	397.696	/	2113.9275
=	18.81 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(629.605	+	1468.923	+	167.666)	-	(1120.882	+	0	+	229.465)
=	915.847

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(595.189	+	1541.693	+	186.197)	-	(1215.712	+	0	+	228.362)
=	879.005

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Raia Drogasil's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	105.435	/	1827.482
	=	5.77 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Raia Drogasil Operating Income Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Raia Drogasil (Raia Drogasil) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (OTCPK:RADLY) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

RADL3:Brazil

Address

Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000

Website

https://ri.rd.com.br

Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.